David  Shapiro net worth and biography

David Shapiro Biography and Net Worth

Dr. David Shapiro is the founder, president, and CEO of Integrated Quality Resources (IQR), a consulting company focused on development stage biopharmaceutical companies. Previously, he served as chief medical officer and executive vice president for research and development at Intercept Pharmaceuticals. 

Dr. Shapiro’s clinical development experience spans over 30 years in the pharmaceutical industry. He has been in his role with IQR since 1998, and he spent 12 years with Intercept from 2007 to 2019. Additionally, he served as CMO and executive vice president, medical affairs for Idun Pharmaceuticals (later acquired by Pfizer) from 2000 to 2005. Prior to Idun, he served as president of the Scripps Medical Research Center at Scripps Clinic from 1995 to 1998. 

Previously, he held research positions at Gensia Pharmaceuticals and Merck Research Laboratories. 

Dr. Shapiro has authored over 20 peer-reviewed publications, and he has also organized and chaired multiple conferences focused on improving product development. He is an elected fellow of London’s Royal College of Physicians and the Faculty of Pharmaceutical Physicians of the United Kingdom. He currently serves on the board of directors of Galecto, Inc., a clinical stage biotechnology company focused on fibrosis and cancer treatments. 

Dr. Shapiro earned his M.D. from Dundee University Medical School, and he completed his internal medicine residency program through Oxford University Teaching Hospitals.

What is David Shapiro's net worth?

The estimated net worth of David Shapiro is at least $262,542.00 as of February 19th, 2021. Dr. Shapiro owns 13,818 shares of Intercept Pharmaceuticals stock worth more than $262,542 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Shapiro may own. Learn More about David Shapiro's net worth.

How do I contact David Shapiro?

The corporate mailing address for Dr. Shapiro and other Intercept Pharmaceuticals executives is 10 Hudson Yards 37th FL, New York NY, 10001. Intercept Pharmaceuticals can also be reached via phone at (646) 747-1000 and via email at [email protected]. Learn More on David Shapiro's contact information.

Has David Shapiro been buying or selling shares of Intercept Pharmaceuticals?

David Shapiro has not been actively trading shares of Intercept Pharmaceuticals within the last three months. Most recently, David Shapiro sold 2,000 shares of the business's stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $86.28, for a transaction totalling $172,560.00. Following the completion of the sale, the insider now directly owns 41,499 shares of the company's stock, valued at $3,580,533.72. Learn More on David Shapiro's trading history.

Who are Intercept Pharmaceuticals' active insiders?

Intercept Pharmaceuticals' insider roster includes Srinivas Akkaraju (Director), and David Shapiro (Insider). Learn More on Intercept Pharmaceuticals' active insiders.

David Shapiro Insider Trading History at Intercept Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2019Sell2,000$86.28$172,560.0041,499View SEC Filing Icon  
4/15/2019Sell2,000$95.00$190,000.0041,499View SEC Filing Icon  
4/3/2019Sell562$115.01$64,635.6240,061View SEC Filing Icon  
3/1/2019Sell2,000$103.16$206,320.0042,543View SEC Filing Icon  
2/15/2019Sell2,000$111.51$223,020.0042,543View SEC Filing Icon  
1/4/2019Sell474$97.48$46,205.5237,243View SEC Filing Icon  
1/2/2019Sell2,000$98.28$196,560.0038,416View SEC Filing Icon  
12/17/2018Sell2,000$106.62$213,240.0041,152View SEC Filing Icon  
11/1/2018Sell2,000$96.32$192,640.0041,152View SEC Filing Icon  
10/15/2018Sell3,425$102.95$352,603.7542,577View SEC Filing Icon  
10/5/2018Sell759$110.65$83,983.3539,152View SEC Filing Icon  
9/5/2018Sell4,917$111.43$547,901.3142,196View SEC Filing Icon  
10/2/2017Sell349$58.90$20,556.10View SEC Filing Icon  
9/1/2017Sell1,250$117.43$146,787.5045,812View SEC Filing Icon  
8/1/2017Sell1,118$119.00$133,042.0045,680View SEC Filing Icon  
7/11/2017Sell553$124.01$68,577.5344,562View SEC Filing Icon  
7/3/2017Sell350$121.24$42,434.0045,215View SEC Filing Icon  
5/1/2017Sell1,117$112.18$125,305.0646,582View SEC Filing Icon  
4/10/2017Sell558$108.51$60,548.5845,465View SEC Filing Icon  
4/3/2017Sell346$115.00$39,790.0046,023View SEC Filing Icon  
1/9/2017Sell1,565$106.01$165,905.6540,369View SEC Filing Icon  
1/3/2017Sell988$103.92$102,672.9641,934View SEC Filing Icon  
12/2/2016Sell1,350$99.75$134,662.5042,922View SEC Filing Icon  
10/10/2016Sell411$153.34$63,022.7444,272View SEC Filing Icon  
10/3/2016Sell1,513$163.08$246,740.0446,196View SEC Filing Icon  
9/26/2016Sell3,545$165.08$585,208.6045,732View SEC Filing Icon  
7/5/2016Sell163$145.11$23,652.93View SEC Filing Icon  
4/4/2016Sell165$130.76$21,575.4048,546View SEC Filing Icon  
1/4/2016Sell533$145.90$77,764.7040,911View SEC Filing Icon  
11/16/2015Sell4,264$178.53$761,251.9228,395View SEC Filing Icon  
11/10/2015Sell3,500$204.15$714,525.0029,159View SEC Filing Icon  
10/2/2015Sell1,140$160.12$182,536.8029,159View SEC Filing Icon  
9/15/2015Sell3,500$191.28$669,480.0023,527View SEC Filing Icon  
8/17/2015Sell4,272$209.37$894,428.64View SEC Filing Icon  
7/1/2015Sell3,781$238.66$902,373.46View SEC Filing Icon  
6/15/2015Sell3,500$241.58$845,530.00View SEC Filing Icon  
4/2/2015Sell3,459$275.25$952,089.75View SEC Filing Icon  
3/16/2015Sell3,500$286.90$1,004,150.00View SEC Filing Icon  
1/5/2015Sell664$172.63$114,626.32View SEC Filing Icon  
11/17/2014Sell4,790$158.82$760,747.80View SEC Filing Icon  
10/2/2014Sell5,020$231.63$1,162,782.60View SEC Filing Icon  
10/1/2014Sell4,188$231.17$968,139.96View SEC Filing Icon  
9/15/2014Sell4,000$281.19$1,124,760.00View SEC Filing Icon  
8/27/2014Sell10,000$293.93$2,939,300.00View SEC Filing Icon  
8/15/2014Sell4,774$291.49$1,391,573.26View SEC Filing Icon  
7/2/2014Sell5,036$244.73$1,232,460.28View SEC Filing Icon  
6/16/2014Sell4,000$278.15$1,112,600.00View SEC Filing Icon  
4/2/2014Sell5,393$331.83$1,789,559.1913,679View SEC Filing Icon  
3/17/2014Sell4,456$437.49$1,949,455.4413,124View SEC Filing Icon  
1/8/2014Sell4,928$71.85$354,076.808,663View SEC Filing Icon  
12/16/2013Sell5,016$62.11$311,543.763,000View SEC Filing Icon  
10/2/2013Sell4,392$72.80$319,737.60View SEC Filing Icon  
8/16/2013Sell5,016$49.20$246,787.204,266View SEC Filing Icon  
8/15/2013Sell4,754$45.04$214,120.162,532View SEC Filing Icon  
7/2/2013Sell4,369$43.63$190,619.47View SEC Filing Icon  
6/17/2013Sell5,016$32.72$164,123.52View SEC Filing Icon  
5/16/2013Sell5,016$31.31$157,050.96View SEC Filing Icon  
4/9/2013Sell3,750$34.41$129,037.50View SEC Filing Icon  
See Full Table

David Shapiro Buying and Selling Activity at Intercept Pharmaceuticals

This chart shows David Shapiro's buying and selling at Intercept Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intercept Pharmaceuticals Company Overview

Intercept Pharmaceuticals logo
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Read More

Today's Range

Now: $19.00
Low: $19.00
High: $19.00

50 Day Range

MA: $18.88
Low: $18.20
High: $19.00

2 Week Range

Now: $19.00
Low: $8.82
High: $21.86

Volume

N/A

Average Volume

1,362,029 shs

Market Capitalization

$794.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88